Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Shares Outstanding (Diluted Average): 2017-2025

Historic Shares Outstanding (Diluted Average) for Coherus Oncology (CHRS) over the last 8 years, with Sep 2025 value amounting to $116.2 million.

  • Coherus Oncology's Shares Outstanding (Diluted Average) rose 0.88% to $116.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $116.2 million, marking a year-over-year increase of 0.88%. This contributed to the annual value of $114.8 million for FY2024, which is 21.95% up from last year.
  • Per Coherus Oncology's latest filing, its Shares Outstanding (Diluted Average) stood at $116.2 million for Q3 2025, which was up 0.13% from $116.1 million recorded in Q2 2025.
  • Over the past 5 years, Coherus Oncology's Shares Outstanding (Diluted Average) peaked at $116.2 million during Q3 2025, and registered a low of $72.8 million during Q1 2021.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $105.8 million, with a median of $114.8 million in 2024.
  • Per our database at Business Quant, Coherus Oncology's Shares Outstanding (Diluted Average) decreased by 14.78% in 2021 and then surged by 42.24% in 2024.
  • Over the past 5 years, Coherus Oncology's Shares Outstanding (Diluted Average) (Quarterly) stood at $75.4 million in 2021, then grew by 2.89% to $77.6 million in 2022, then climbed by 21.30% to $94.2 million in 2023, then grew by 21.95% to $114.8 million in 2024, then increased by 0.88% to $116.2 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $116.2 million in Q3 2025, compared to $116.1 million in Q2 2025 and $115.9 million in Q1 2025.